Expert Kidney Cancer Care
World leaders in robotic kidney cancer surgery.
When you’re diagnosed with kidney cancer, you want the most experienced specialists on your care team. We pioneered a kidney-sparing surgical procedure – called robotic partial nephrectomy – and developed innovative techniques to preserve kidney function during surgery and to shorten your hospital stay.
Your Henry Ford cancer team will include surgeons who are among the most experienced in the United States and world, having performed more than 1,200 robotic urologic surgeries. You’ll also have a dedicated cancer nurse to support you throughout your care and assist with appointment scheduling.
Our cancer team is available 24/7. Call us at 888-777-4176.
The kidney cancer team at Henry Ford Cancer Institute will be with you every step of the way – from diagnosis and treatment through recovery.
Innovative treatment from the most experienced surgeons
Our patients have access to the top kidney cancer surgeons and innovative robotic surgical treatment options. We take your cancer diagnosis, health needs and concerns into account to create a personalized treatment plan. Our team uses the most advanced techniques, including kidney-saving surgery, whenever possible, to offer you the best outcome.
- Minimally invasive robot-assisted surgery, including robotic partial nephrectomy, which removes the cancer while preserving the normal and unaffected portion of the kidney
- Cryoablation, a nonsurgical treatment we use to freeze and destroy small kidney tumors
- Traditional open surgery, which is needed in rare cases where tumors are large, complex, or invasive
- Advanced chemotherapy treatments to help shrink kidney cancer tumors that have spread (metastasized) to other areas of the body
- Clinical trials
Our team, led by Dr. Craig Rogers, the top kidney cancer surgeon in the Midwest, continuously work to develop new treatment options, for even the most advanced kidney cancers.
In 2015, we were the first in the world to perform a new procedure for metastatic kidney cancer. The procedure involved suctioning a kidney cancer tumor from a patient’s vena cava (a vein that carries blood into the heart), followed by minimally invasive kidney removal surgery. The patient then participated in a clinical trial that used genetic material from the tumor to produce a vaccine to fight the disease.